Archive for the 'Chronic hepatitis C' Category

03 Aug

High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C: DISCUSSION (Part 2)

The high dose therapy with CIFN, given during the initial 12-week induction phase in the present study, had a high side effect profile. The symptoms precipitating withdrawal from CIFN therapy in the present group of highly motivated patients were systemic, namely weakness, irritability and, in one patient, profound confusion. These side effects were maximal during […]

02 Aug

High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C: DISCUSSION (Part 1)

As expected, our patient population of nonresponders to IFN alpha-2b and ribavirin had characteristics typical of those with a poor response to antiviral therapy (ie, genotypes 1 and 4, cirrhosis on liver biopsy and male sex). The present study indicates that some patients with hepatitis C infection, although resistant to full doses of standard IFN […]

01 Aug

High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C: RESULTS (Part 2)

Of the 18 patients who completed 12 weeks of therapy, nine (38%) had undetectable HCV RNA at the time and, thus, continued with treatment. Seven of these nine patients completed 48 weeks of treatment and two patients withdrew, again because of intolerable side effects (ie, fatigue in one patient, and fatigue, myalgias and arthralgias in […]

31 Jul

High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C: RESULTS (Part 1)

There were 24 patients enrolled in the study; 20 (83%) of the patients were male. The mean age of patients was 49 years. The HCV genotype distribution in the 24 patients was genotype 1, 18 patients (75%); genotype 2, one patient (4%); genotype 3, one patient (4%); and genotype 4, four patients (17%). Thirteen patients […]

30 Jul

High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C: METHODS (Part 2)

Patients were to receive 15 |ag CIFN daily for the first three months when a qualitative HCV RNA test was done. Patients with persistently detectable HCV RNA at week 12 had their treatment stopped. Those with undetectable HCV RNA were to continue treatment at a dose of 15 |ag subcutaneously three times per week for […]

29 Jul

High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C: METHODS (Part 1)

Study design Patients were selected from our department of medicine database. To be eligible for the study, patients had to have detectable HCV RNA in their serum and persistently elevated serum alanine aminotransferase levels at least 1.5 times the upper limit of normal. Eligible patients also had to have completed a full course of IFN […]

28 Jul

High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C (Part 2)

Consensus IFN (CIFN) is a genetically engineered molecule derived by aligning the sequences of all known alpha IFN s and assigning the most commonly observed amino acid in each sequence. Studies have shown that treatment of naive subjects with HCV infection with 9 |ag CIFN gives a sustained virological response similar to that of standard […]

27 Jul

High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C (Part 1)

Hepatitis C virus (HCV) is a single-stranded, positive-sense RNA virus belonging to the Flaviviridae family. Fifty per cent to 80% of people infected develop a chronic infection. A proportion of patients ultimately develop cirrhosis and hepatocellular carcinoma. The lifetime risk of cirrhosis in an HCV carrier is about 20% but may be higher depending on […]

© 2017 - Men’s Health Info Blog